Advances in peptide drug development and the rising prevalence of hematological disorders are driving demand for peptide-based therapeu ...

The blow fill seal technology market is expected to grow from its estimated USD 3,107.8 million in 2024 to USD 5,258.5 million in 2034. Between 2024 and 2034, sales are expected to increase at a ...

The incidence and prevalence of genital herpes simplex virus (HSV) type 1 and 2 infections are high worldwide, contributing ...

Sweid One is a pivotal project for us, designed to raise the bar for commercial office space within JLT,” said Maher Sweid, ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today. The company’s shares opened today at ...

Massachusetts families are still struggling to find alternatives almost a year after GlaxoSmithKline canceled a widely ...

Maud Gatewood (1934–2004) is an essential figure in mid- and late-20th century art in North Carolina, both as an esteemed ...

British drugmaker AstraZeneca has appointed a new China head, replacing a former executive who has been detained by ...